GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Galderma Group AG (FRA:PY30) » Definitions » Investments And Advances

Galderma Group AG (FRA:PY30) Investments And Advances : €0 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Galderma Group AG Investments And Advances?

Galderma Group AG's Investments And Advances for the quarter that ended in Dec. 2024 was €0 Mil.

Galderma Group AG Investments And Advances Historical Data

The historical data trend for Galderma Group AG's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galderma Group AG Investments And Advances Chart

Galderma Group AG Annual Data
Trend Dec23 Dec24
Investments And Advances
- -

Galderma Group AG Semi-Annual Data
Jun23 Dec23 Jun24 Dec24
Investments And Advances - - - -

Galderma Group AG Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.

Galderma Group AG Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Galderma Group AG (FRA:PY30) » Definitions » Investments And Advances
Comparable Companies
XSWX:SDZ XSWX:SFZN XSWX:PPGN XSWX:CURN ZTS XTER:MRK LSE:HLN NSE:SUNPHARMA TSE:4502 NSE:DIVISLAB HKSE:03692 XTAE:TEVA SHSE:688506 BOM:500087 SZSE:000538 TSE:4507 UTHR NSE:TORNTPHARM BOM:500124 NBIX
Traded in Other Exchanges
GALDY:USA GDERF:USA GALDz:UK PY3:Germany GALD:Switzerland
Address
Zahlerweg 10, Zug, CHE, 6300
Website
https://www.galderma.com
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a standalone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 45% of net sales from the US and employs around 6,600 people.

Galderma Group AG Headlines

No Headlines